Drugs / JR-171
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04453085 | Oct 2021 → May 2025 | mucopolysaccharidosis type 1 | JCR Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04227600 | Sep 2020 → Aug 2022 | mucopolysaccharidosis type 1 | JCR Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JR-171 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04227600 ↗ |
| Known as | lepunafusp alfa | “We have developed a novel genetically modified protein consisting of IDUA fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa; JR-171), which has...” PMID 38204164 ↗ Jan 2024 |
| Modality | Protein / enzyme biologic | “a novel genetically modified protein consisting of IDUA fused with humanized anti-human transferrin receptor antibody” PMID 38204164 ↗ Jan 2024 |
| Route | Intravenous | “IV infusion” NCT04227600 ↗ |